Mariner
AXSM icon

Mariner’s Axsome Therapeutics AXSM Stock Holding History

Mariner’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
18,262
+1,448
+9% +$314K ﹤0.01% 1086
2026
Q1 		$2.84M Buy
16,814
+1,526
+10% +$264K ﹤0.01% 1337
2025
Q4 		$2.79M Sell
15,288
-1,329
-8% -$186K ﹤0.01% 1310
2025
Q3 		$2.02M Buy
16,617
+1,023
+7% +$115K ﹤0.01% 1431
2025
Q2 		$1.63M Buy
15,594
+823
+6% +$87.1K ﹤0.01% 1471
2025
Q1 		$1.72M Sell
14,771
-349
-2% -$39.8K ﹤0.01% 1325
2024
Q4 		$1.28M Buy
15,120
+1,834
+14% +$169K ﹤0.01% 1485
2024
Q3 		$1.19M Buy
13,286
+10,149
+324% +$886K ﹤0.01% 1476
2024
Q2 		$253K Buy
3,137
+523
+20% +$38.7K ﹤0.01% 2588
2024
Q1 		$209K Sell
2,614
-115
-4% -$9.65K ﹤0.01% 2735
2023
Q4 		$217K Buy
+2,729
New +$182K ﹤0.01% 2626
2019
Q3 		– Sell
-23,025
Closed -$593K – 711
2019
Q2 		$593K Buy
23,025
+1,500
+7% +$30.1K 0.01% 671
2019
Q1 		$306K Sell
21,525
-20,000
-48% -$186K ﹤0.01% 807
2018
Q4 		$117K Hold
41,525
– – ﹤0.01% 803
2018
Q3 		$143K Hold
41,525
– – ﹤0.01% 780
2018
Q2 		$133K Hold
41,525
– – ﹤0.01% 762
2018
Q1 		$102K Hold
41,525
– – ﹤0.01% 617
2017
Q4 		$233K Hold
41,525
– – 0.01% 501
2017
Q3 		$230K Hold
41,525
– – 0.01% 455
2017
Q2 		$228K Sell
41,525
-4,475
-10% -$18.7K 0.01% 450
2017
Q1 		$179K Buy
46,000
+1,000
+2% +$4.78K 0.01% 555
2016
Q4 		$304K Hold
45,000
– – 0.01% 442
2016
Q3 		$355K Buy
45,000
+3,475
+8% +$26.3K 0.02% 432
2016
Q2 		$313K Buy
+41,525
New +$382K 0.02% 413

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mariner's AXSM Position: Q2 2026 in Review

Mariner increased its Axsome Therapeutics (AXSM) stake by 8.6% in Q2 2026, buying an estimated $314K and bringing the position to 18,262 shares worth $4.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Mariner first reported a position in AXSM in Q2 2016 and has held it in 24 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Mariner held 18,262 shares of Axsome Therapeutics worth $4.47M as of Q2 2026.
  • Mariner bought 1,448 Axsome Therapeutics shares in Q2 2026, an estimated $314K.
  • Axsome Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1086 holding.
  • Mariner first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 24 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.